SYDNEY: TrivarX Ltd (ASX: TRI) said on Thursday it will acquire the intellectual property for Stabl-Im™, a novel brain cancer imaging technology, from Australian biotech firm Nucleics Pty Ltd, in a deal aimed at expanding its diagnostics portfolio into neuro-oncology. The Perth and Minneapolis-based company has entered a binding option agreement to acquire 100%…
SYDNEY, AUSTRALIA: Race Oncology Limited announced that Mr Damian Clarke-Bruce has been appointed Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his prior role as a Non-Executive Director of Race Oncology and will work closely with Mr Clarke-Bruce to ensure a smooth and effective leadership transition.…